Article Information
History
- February 2, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Irina Kislaya1,2,3,*,†,
- André Peralta-Santos2,3,4,*,
- Vítor Borges5,
- Luís Vieira6,
- Carlos Sousa7,
- Bibiana Ferreira8,9,
- Ana Pelerito10,
- João Paulo Gomes5,
- Pedro Pinto Leite4,
- Baltazar Nunes1,2,3 and
- PT COVID-19 group**
- 1Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal
- 2Public Health Research Centre, NOVA National School of Public Health, Universidade NOVA de Lisboa, Lisbon, Portugal
- 3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa, Lisbon, Portugal
- 4Direção de Serviços de Informação e Análise, Direção-Geral da Saúde, Lisbon, Portugal
- 5Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal
- 6Unidade de Tecnologia e Inovação, Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
- 7Unilabs, Porto, Portugal
- 8Algarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal
- 9Faculty of Medicine and Biomedical Sciences (FMCB), Campus de Gambelas, University of Algarve, Faro, Portugal
- 10Portuguese Red Cross Laboratory, Lisbon Portugal
- ↵†Corresponding author: Irina Kislaya, Corresponding author email: irina.kislaya{at}insa.min-saude.pt
↵* Equal contributions
Posted February 02, 2022.
Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants
